Menu

Investors

2026 Third quarter results announcement​

We will announce our third quarter 2026​ results on 28 October at 07:00 GMT, 03:00 EDT. ​

Quarterly resultsRegister for the webcast
Close video

Who we are

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.

Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.​

Respiratory, immunology and inflammation
7m
deaths each year due to lung diseases
Go to respiratory, immunology and inflammation
Oncology
~10m
people die from cancer each year
Go to oncology
HIV
40m
people living with HIV globally
Go to HIV
Infectious diseases
1 in 7
deaths globally caused by infectious disease
Go to infectious diseases

Behind the Science

Exploring how today's discoveries are shaping tomorrow's health

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

Read our magazine

INVESTORS

We will announce our third quarter 2026 results on Wednesday 28 October

View latest results

Continue to Company